

# Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study

Paul Welsh <sup>a,\*†</sup> Dorien M. Kimenai,<sup>b,†</sup> Anoop S.V. Shah,<sup>c</sup> Danni A. Gadd,<sup>d</sup> Riccardo E. Marioni,<sup>d</sup> Mark Woodward,<sup>e,f</sup> Cathie L.M. Sudlow,<sup>g,h</sup> Archie Campbell <sup>d</sup>, John G.F. Cleland,<sup>a</sup> Pierpaolo Pellicori <sup>a</sup>, Caroline Hayward,<sup>i</sup> Nicholas L. Mills <sup>b,h,†</sup> and Naveed Sattar <sup>a,†</sup>

**BACKGROUND:** Many studies have investigated whether single cardiac biomarkers improve cardiovascular risk prediction for primary prevention but whether a combined approach could further improve risk prediction is unclear. We aimed to test a sex-specific, combined cardiac biomarker approach for cardiovascular risk prediction.

**METHODS:** In the Generation Scotland Scottish Family Health Study, N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15), cardiac troponin I (cTnI), cardiac troponin T (cTnT), and C-reactive protein (CRP) were measured in stored serum using automated immunoassays. Sex-specific Cox models that included SCORE2 risk factors evaluated addition of single and combined biomarkers for prediction of major adverse cardiovascular events (MACE). Combined biomarker models were compared to a baseline model that included SCORE2 risk factors.

**RESULTS:** The study population comprised 18 383 individuals (58.9% women, median age of 48 years

[25th–75th percentile, 35–58 years]). During the median follow up of 11.6 (25th–75th percentile, 10.8–13.0) years, MACE occurred in 942 (5.1%) individuals. The greatest increase in discrimination with addition of individual biomarkers to the base model was for women GDF-15 and for men NT-proBNP (change in c-index: +0.010 for women and +0.005 for men). For women, combined biomarker models that included GDF-15 and NT-proBNP (+0.012) or GDF-15 and cTnI (+0.013), but not CRP or cTnT, further improved discrimination. For men, combined biomarker models that included NT-proBNP and GDF-15 (+0.007), NT-proBNP and cTnI (+0.006), or NT-proBNP and CRP (+0.008), but not cTnT, further improved discrimination.

**CONCLUSIONS:** A combined biomarker approach, particularly the use of GDF-15, NT-proBNP and cTnI, further refined cardiovascular risk estimates.

## Introduction

Cardiovascular risk estimation is one of the cornerstones of the primary prevention of cardiovascular disease (1, 2). A biomarker-driven approach may refine cardiovascular risk estimates because disease-specific biomarkers can provide additional information about the presence and extent of asymptomatic cardiovascular disease which could help improve individual risk prediction.

Previous studies have shown that N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15), cardiac troponin I (cTnI), cardiac troponin T (cTnT), and C-reactive protein (CRP) predict cardiovascular events in people with established cardiovascular disease, and in the general population (3–12). Elevations in these biomarkers reflect different underlying pathophysiological features of cardiovascular disease, including myocardial ischemia or injury (cTnI, cTnT), cardiac wall stretch or remodeling (NT-proBNP), inflammation (CRP), and generalized tissue damage (GDF-15). Previous studies have

<sup>a</sup>School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, United Kingdom; <sup>b</sup>BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; <sup>c</sup>Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom; <sup>d</sup>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom; <sup>e</sup>The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom; <sup>f</sup>The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; <sup>g</sup>British Heart Foundation Data Science Centre, Health Data Research UK, London, United Kingdom; <sup>h</sup>Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; <sup>i</sup>MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.

\*Address correspondence to this author at: School of Cardiovascular and Metabolic Health, The University of Glasgow, 126 University Pl., Glasgow, G12 8TA, United Kingdom. E-mail paul.welsh@glasgow.ac.uk.

Previous presentation: ACC.23/WCC (March 4–6, 2023, New Orleans, United States).

†These authors contributed equally.

Received June 21, 2023; accepted October 27, 2023.  
<https://doi.org/10.1093/clinchem/hvad205>

investigated whether single or combined cardiac biomarker approaches may improve risk prediction for primary prevention of cardiovascular disease (13–16). However, whether a combined biomarker approach, using assays relevant to contemporary clinical biochemistry settings, could further improve prediction of risk in both sexes is unclear. Important sex differences are observed between the relationship of cardiac biomarkers and cardiovascular disease (17–19), and studies of large size are required for sex-specific evaluation of candidate cardiac biomarkers and their combinations.

We hypothesized that cardiac biomarkers would enhance the prediction of cardiovascular events compared to using conventional risk factors alone, and that an approach that used a combination of biomarkers would be superior to the use of any single biomarker in both women and men. Accordingly, we evaluated associations between NT-proBNP, GDF-15, cTnI, cTnT, and CRP and major adverse cardiovascular events (MACE) in the Generation Scotland Scottish Family Health Study (GS:SFHS).

## Materials and Methods

Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols should be sent to the Generation Scotland management team at [access@generationscotland.org](mailto:access@generationscotland.org).

### STUDY POPULATION

The GS:SFHS is a family-based cohort that enrolled 24 090 participants between 18 and 98 years of age (20, 21). Briefly, individuals between 35 and 65 years old were identified at random from participating general practices in Scotland between February 2006 and March 2011. Participants were then asked to identify one or more first-degree relatives  $\geq 18$  years old who would also be able to participate. For this study, we excluded participants with cardiovascular disease at baseline, those who had missing cardiac biomarker measurements, or who did not attend the clinical survey. As GDF-15 concentrations are temporarily substantially increased during pregnancy, we also excluded pregnant women (self-reported or when GDF-15 concentrations were  $>10\,000$  pg/mL in women  $\leq 45$  years old) (22). Participants completed a health questionnaire, and clinical characteristics were measured using a standardized protocol. The cohort is almost entirely of White ethnicity (99%) (20) and therefore ethnicity is not further reported in this study. Study participants provided written informed consent, including linkage to their medical records. Ethical approval for the GS:SFHS study was obtained from the National Health Service Tayside Research Ethics Committee (Research

Ethics Committee reference number 05/S1401/89). The study was conducted according to principles of the Declaration of Helsinki and follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

### BIOMARKER MEASUREMENTS

Serum concentrations of NT-proBNP, GDF-15, high-sensitivity cTnT, and high-sensitivity CRP were measured on a Cobas e411 analyzer (Roche Diagnostics). Serum concentration of high-sensitivity cTnI was measured on an ARCHITECT i1000SR analyzer (Abbott Diagnostics). cTnI and cTnT were measured on a first thaw (measured 2016 to 2017) (3), with NT-proBNP and GDF-15 measured on a second thaw (measured 2020 to 2021), and CRP on a third thaw (measured 2021 to 2022). For NT-proBNP, GDF-15, and CRP, the limit of detection (LOD) is set to 10 pg/mL, 400 pg/mL, and 0.1 mg/L by the manufacturer, respectively. For these biomarkers we reported anything less than the LOD at LOD/2 for continuous analysis (5 pg/mL for NT-proBNP, 200 pg/mL for GDF-15, and 0.05 mg/L for CRP). For cTnT, the limit of blank (LOB) and LOD are 3 and 5 ng/L according to the manufacturer, respectively. For cTnI, the LOB and LOD are 1.2 and 1.9 ng/L, respectively (23). For the primary analysis, cTnT and cTnI concentrations below the LOB are set to the LOB value divided by 2 (cTnT, 1.5 ng/L; cTnI, 0.6 ng/L). Proportions of samples above the LOB or LOD are reported in [Supplemental Table 1](#) in the online Data Supplement. During the conduct of this study, we participated in the National External Quality Assurance Scheme (UKNEQAS) for selected biomarkers (cTnI, cTnT, and NT-proBNP). The assays were calibrated, and quality controlled using the manufacturers' reagents.

### CLINICAL OUTCOMES

We used the Information Services Division NHS record linkage for Scotland to collect nonfatal cardiovascular events and cause-specific deaths data until the end of August 2021. Information on cause of death was obtained using the NHS Central Register. Nonfatal cardiovascular events and cause-specific deaths were classified using the 10th revision of the International Classification of Diseases (ICD-10). The primary outcome was a composite end point of MACE that included nonfatal myocardial infarction (I21, I22), nonfatal stroke (I63, I64, G45), or cardiovascular death (all codes between I00 and I99). Secondary outcomes were the individual end points of myocardial infarction (nonfatal and fatal, I21, I22), ischemic stroke (nonfatal and fatal, I63, I64, G45), cardiovascular death (all codes between I00 and I99), and noncardiovascular

death (other ICD-10 codes not classed as cardiovascular).

#### STATISTICAL ANALYSIS

The correlation between circulating biomarkers was assessed by Spearman correlation. We determined the proportion of individuals above either diagnostic or prognostic biomarker thresholds according to clinical guidelines or established thresholds for the normal range [NT-proBNP >125 pg/mL (24), GDF-15 >4000 pg/mL (25), cTnI >26.2 ng/L (26), cTnT >14 ng/L (26), and CRP >2 mg/L (27)].

We used sex-specific Cox proportional hazard regression models to quantify the relationship between individual biomarkers and MACE. We assessed the impact of using a competing risk framework on biomarker–MACE risk associations, and concluded the differences in risk associations were so marginal that implementing a competing risk framework was not justified in this study. Adjusted sex-specific regression models included the SCORE2 risk factors (age, smoking status, systolic blood pressure, diabetes mellitus, total cholesterol, and high-density lipoprotein cholesterol) and as such did not include adjustment for body mass index (28). Biomarkers were entered in the model as continuous variables. For each biomarker, we applied  $\log_2$  transformation and examined them per 1 SD increase in the model accordingly. We bootstrapped the ratio of the hazard ratios (HRs) to compare the strength of the association of individual biomarkers with MACE in the adjusted model, using the HR for NT-proBNP as the denominator. We constructed HR plots to illustrate the relationship between biomarkers and MACE and used natural cubic splines to account for nonlinear relationships between a biomarker and MACE. The proportional hazards assumption was tested by plotting Schoenfeld residuals.

We evaluated combined biomarker approaches in relation to MACE using sex-specific Cox proportional hazard regression models. We assessed all possible combinations for NT-proBNP, GDF-15, cTnI, cTnT, and CRP and entered the biomarkers as continuous variables into the model ( $\log_2$  transformed and examined per 1 SD in the model). Similar covariates were included in the models as in the single-biomarker models. We also evaluated discrimination for each biomarker individually and in combination using the Harrell c-statistic, the integrated discrimination index (IDI), and net reclassification index (NRI, continuous and categorical). Testing every possible biomarker combination increases the number of statistical tests conducted, but allows each biomarker combination to be evaluated on the basis of incremental discriminative ability. In addition, the age-specific performance of biomarker models was evaluated for those <40 and  $\geq$ 40 years old.

Secondary analyses were conducted to verify the robustness of our findings. First, we set cTnI and cTnT concentrations below the LOD at the LOD divided by 2 (rather than using LOB). Second, we evaluated discrimination of biomarker models compared to a base model using SCORE2 risk factors and socioeconomic deprivation status. Socioeconomic deprivation status was determined using the Scottish Index of Multiple Deprivation 2009 score, which is derived from participants' postal codes and compiled using 7 domains of deprivation (income, employment, education, health, access to services, crime, and housing) (29). Third, we additionally evaluated the kidney biomarker creatinine in relation to our primary outcome; we used raw creatinine rather than estimated glomerular filtration rate (eGFR) as a biomarker in order to avoid adjusting eGFR for risk factors already included in its calculation (i.e., age). And finally, we evaluated the associations between biomarkers and secondary outcomes. For completion, we also evaluated the association for all-cause death.

Familial clustering did not affect our analyses, and therefore we only present results from analyses without adjustment for clustering. Multiple imputation by chained equations was used to account for missing data for risk factors (but not missing biomarker concentrations) in the Cox regression models (10 imputed data sets). Statistical analysis was performed using R version 3.6.2.

## Results

### CLINICAL CHARACTERISTICS OF STUDY POPULATION

The cohort comprised 18 383 individuals (58.9% women, median age 48 [25th–75th percentile, 35–58; range 18–94] years; Table 1). Cardiac biomarker concentrations were generally low; 15.0% had an NT-proBNP above 125 pg/mL, 0.8% had a GDF-15 >4000 pg/mL, 0.8% had a cTnI >26.2 ng/L, 2.6% had a cTnT >14 ng/L, and 33.9% had a CRP >2 mg/L.

MACE occurred in 717 (4.0%) of individuals over 10 years (online Supplemental Table 2) and in 942 (5.1%) individuals during the total median follow-up of 11.6 (25th–75th percentile, 10.8–13.0) years. In both women and men, baseline concentrations of biomarkers were higher in those who later experienced MACE compared to those who did not (Table 1 and online Supplemental Table 3). We observed moderate and broadly similar correlations between circulating cardiac biomarkers, with CRP generally showing the weakest correlation with other biomarkers (online Supplemental Fig. 1).

### THE ASSOCIATION OF CIRCULATING BIOMARKERS WITH CARDIOVASCULAR EVENTS

In unadjusted, single biomarker models, NT-proBNP had numerically the strongest and CRP had the weakest

**Table 1. Baseline characteristics of study participants with and without incident MACE on follow-up.<sup>a,b</sup>**

	All (n = 18 383)	No incident MACE (n = 17 441)	Incident MACE (n = 942)
Age, years	48 (35 to 58)	47 (35 to 57)	61 (54 to 69)
Sex, male	7553 (41.1%)	7025 (40.3%)	528 (56.1%)
Body mass index, kg/m <sup>2</sup>	26.6 (5.2)	26.5 (5.1)	28.0 (5.2)
Systolic blood pressure, mmHg	131 (18)	131 (17)	142 (20)
Total cholesterol, mmol/L	5.1 (1.1)	5.1 (1.1)	5.4 (1.2)
High-density lipoprotein cholesterol, mmol/L	1.5 (0.4)	1.5 (0.4)	1.4 (0.4)
SIMD, score/10	1.2 (0.7 to 2.2)	1.1 (0.7 to 2.2)	1.3 (0.7 to 2.5)
eGFR, mL/min/1.73 m <sup>2</sup>	96 (17)	96 (17)	83 (18)
Current smoking, yes	2883 (16.2%)	2696 (16.0%)	187 (20.8%)
Family history of CVD, yes	6966 (38.7%)	6589 (38.6%)	377 (40.9%)
Diabetes mellitus, yes	433 (2.4%)	360 (2.1%)	73 (7.7%)
Lipid modifying medication, yes	931 (5.1%)	798 (4.6%)	133 (14.1%)
Antihypertensive medication, yes	1270 (6.9%)	1093 (6.3%)	177 (18.8%)
NT-proBNP, pg/mL	50.6 (26.4 to 91.5)	49.4 (26.0 to 88.8)	78.5 (40.7 to 174.3)
GDF-15, pg/mL	807.0 (608.1 to 1103.0)	791.1 (601.3 to 1072.0)	1241.0 (884.4 to 1799.8)
cTnI, ng/L	1.9 (0.6 to 3.0)	1.8 (0.6 to 2.9)	2.9 (2.0 to 5.1)
cTnT, ng/L	3.2 (1.5 to 5.8)	3.1 (1.5 to 5.6)	5.7 (1.5 to 9.8)
CRP, mg/L	1.2 (0.6 to 2.8)	1.2 (0.6 to 2.7)	1.8 (0.9 to 3.9)


<sup>a</sup>Continuous variables are presented as mean (SD) or median (25th to 75th percentile), as appropriate. Categorical variables are presented as number (%). Missing values <5% if applicable, except for SIMD (5.7%).  
<sup>b</sup>Abbreviations: SIMD, Scottish Index Multiple Deprivation score; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; GDF-15, growth differentiation factor-1; cTnI, cardiac troponin I; cTnT, cardiac troponin T; CRP, C-reactive protein; MACE, major adverse cardiovascular events.

association with MACE in both sexes (Figs. 1 and 2, and Table 2). After adjusting for conventional risk factors included in the SCORE2 risk equation, the HR of NT-proBNP per 1 SD increase on the log scale was 1.56 (95% CI, 1.38–1.75) and 1.34 (95% CI, 1.22–1.47) for women and men, respectively. GDF-15 and cTnI had a similar relationship with MACE with overlapping confidence intervals in both sexes (women: HR 1.49 [95% CI, 1.35–1.60] and HR 1.42 [95% CI, 1.27–1.58], men: HR 1.34 [95% CI, 1.22–1.47] and HR 1.24 [95% CI, 1.13–1.37]). In contrast, the relationship with MACE was weaker for cTnT and CRP compared to NT-proBNP.

#### COMBINING BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR EVENTS

Discrimination of the base model using SCORE2 risk factors was excellent for both women and men (*c*-indices 0.826 and 0.795, respectively). As compared with the baseline model, GDF-15 improved the *c*-index by +0.010 with an IDI of 0.015 for women (Fig. 3 and

online Supplemental Tables 4–7). For women, combined biomarker models that included GDF-15 together with NT-proBNP (+0.012), or GDF-15 plus cTnI (+0.013), but not CRP or cTnT, further improved the *c*-index. As compared with the baseline model, NT-proBNP improved the *c*-index by +0.005 with an IDI of 0.014 for men (Fig. 3 and Supplemental Tables 4–7). For men, combined biomarker models that included NT-proBNP together with GDF-15 (+0.007), NT-proBNP plus cTnI (+0.006), and NT-proBNP plus CRP (+0.008), but not cTnT, further improved the *c*-index. The greatest numerical improvement in discrimination from the base model was achieved with NT-proBNP, GDF-15, and cTnI for women (+0.014) and NT-proBNP, GDF-15, cTnI, and CRP for men (+0.010) (Fig. 3). The combined model incorporating NT-proBNP, GDF-15, and cTnI yielded an IDI of +0.033 and a continuous NRI of +0.254 in women (online Supplemental Tables 6 and 8). The combined model incorporating NT-proBNP, GDF-15, cTnI, and CRP yielded an IDI of +0.017



**Fig. 1. Crude association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), GDF-15 (growth differentiation factor-15), cardiac troponin T (cTnT), cardiac troponin I (cTnI), and C-reactive protein (CRP) with major adverse cardiovascular events (MACE) in women (A) and men (B).**

and a continuous NRI of +0.120 in men (online Supplemental Tables 6 and 9). Generally, cardiac biomarkers improved risk classification among cases more than non-cases.

The base SCORE2 models performed better in individuals aged <40 years compared to those aged ≥40 years (c-index 0.831 vs 0.766, online Supplemental Table 10). Although discriminative performance was weaker in those aged ≥40 years, this group had the greatest improvement in the c-index with the addition of NT-proBNP and GDF-15. For NT-proBNP, the change in c-index, compared with the base model, was +0.001 and +0.008 in individuals aged <40 years and ≥40 years, respectively. For GDF-15, the change in c-index, compared with the base model, was +0.000 and +0.0010 in individuals aged <40 years and ≥40 years, respectively. Conversely, cTnI showed greatest improvement in individuals aged <40 years compared to their counterparts (change in c-index: +0.013 vs +0.006). A combined biomarker model that included NT-proBNP, GDF-15, and cTnI yielded a categorical NRI of +0.048 for individuals ≥40 years (online Supplemental Table 11).


**SECONDARY ANALYSIS**

Our results did not change when we set cTnI and cTnT concentrations below the LOD at the LOD/2 value (online Supplemental Table 12). We observed a similar

pattern in the improvement of discrimination, relative to a base model that also included socioeconomic status, for single and combined biomarker models (online Supplemental Table 13). In addition, we evaluated the association of creatinine with primary outcome. Compared with NT-proBNP, the association with creatinine was weaker (online Supplemental Table 14). After adjustment, we found that higher creatinine was associated with MACE in women (HR 1.16 [95% CI, 1.06–1.28]) but not in men (HR 1.06 [95% CI, 0.96–1.17]). When evaluating biomarkers for secondary outcome, we observed that NT-proBNP was numerically more strongly associated with myocardial infarction than either cTnT or cTnI in crude models, but similar associations were found in adjusted models (online Supplemental Table 15). NT-proBNP and cTnI were not associated with noncardiovascular death in adjusted models for women, although GDF-15, cTnT, and CRP were associated with noncardiovascular death.

**Discussion**

We evaluated multiple cardiac biomarkers to predict MACE in a large population-based cohort study. Our main finding was that combining cardiac biomarkers, particularly NT-proBNP, GDF-15, or cTnI, improved estimates of cardiovascular risk over a base model



using traditional SCORE2 risk factors in both women and men.

Our study has several strengths. First, we used a large, contemporary population-based cohort study of >18 000 individuals with more than 10 years of follow-up. Second, the large number of women and men over a wide age range included in this study allowed us to conduct a sex- and age-specific analysis. Third, we were able to measure 5 candidate biomarkers for the prediction of cardiovascular risk in GS:SFHS. This enabled us to perform a systematic evaluation of combined biomarker approaches for cardiovascular risk prediction. Finally, NT-proBNP, cTnT, cTnI, and CRP were measured using assays that are commonly used in clinical biochemistry services around the world, with CRP, cTnT, and cTnI measured by high-sensitivity assays.

A number of studies have evaluated the ability of circulating cardiac biomarkers to predict cardiovascular disease in populations of presumably healthy individuals (13–16, 30–34). Recently, Wu et al. evaluated the use of multiple circulating biomarkers in addition to established risk factors, and found that the addition of NT-proBNP and cardiac troponins refined cardiovascular

risk estimates (32). Similarly, the Uppsala Longitudinal Study of Adult Men (ULSAM) study of 826 older men, using a research use only proteomics approach, reported NT-proBNP to be the biomarker most strongly associated with cardiovascular disease (14). In line with previous reports, we observed that NT-proBNP, traditionally considered a biomarker of heart failure, was strongly associated with MACE. NT-proBNP was particularly strongly additive to the risk score in those  $\geq 40$  years old, an age at which risk prediction models are more often applied in clinical practice. Given increasing interest in using NT-proBNP in some patient groups to screen for heart failure in the absence of signs and symptoms of the condition (35), these collective findings highlight the advantages of prioritizing NT-proBNP for incorporation in commonly applied cardiovascular risk scores. Although our findings are complementary, we provide additional insights by inclusion of 2 additional cardiac biomarkers, cTnT and GDF-15, because recent studies have shown both are independently associated with future cardiovascular events in the general population (3, 9, 36, 37). Our findings show that GDF-15 should also be considered for cardiovascular risk assessment (32). Blankenberg

**Table 2. Association of biomarkers (per 1 SD increase on the log<sub>2</sub> scale) with major adverse cardiovascular events (MACE) in separate models.<sup>a</sup>**


	NT-proBNP		GDF-15		cTnI		cTnT		CRP	
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
<b>Women</b>										
Crude model	2.62 (2.37 to 2.90)	2.18 (2.04 to 2.32)	1.90 (1.78 to 2.03)	2.11 (1.93 to 2.31)	1.51 (1.37 to 1.66)					
Adjusted model <sup>b</sup>	1.56 (1.38 to 1.75)	1.49 (1.35 to 1.66)	1.42 (1.27 to 1.58)	1.28 (1.15 to 1.43)	1.27 (1.15 to 1.41)					
Ratio of biomarker HR:NT-proBNP HR <sup>c</sup>	Reference	0.96 (0.85 to 1.06)	0.91 (0.80 to 1.02)	0.82 (0.71 to 0.93)	0.82 (0.71 to 0.92)					
<b>Men</b>										
Crude model	2.04 (1.89 to 2.20)	1.82 (1.72 to 1.93)	1.49 (1.39 to 1.60)	1.56 (1.43 to 1.70)	1.50 (1.38 to 1.63)					
Adjusted model <sup>b</sup>	1.34 (1.22 to 1.47)	1.24 (1.13 to 1.37)	1.21 (1.10 to 1.32)	1.04 (0.94 to 1.15)	1.17 (1.07 to 1.29)					
Ratio of biomarker HR:NT-proBNP HR <sup>c</sup>	Reference	0.93 (0.83 to 1.02)	0.90 (0.80 to 0.99)	0.77 (0.67 to 0.87)	0.87 (0.78 to 0.97)					

<sup>a</sup>Abbreviations: NT-proBNP, N-terminal pro-B-type natriuretic peptide; GDF-15, growth differentiation factor-1; cTnI, cardiac troponin I; cTnT, cardiac troponin T; CRP, C-reactive protein; MACE, major adverse cardiovascular events; HR, hazard ratio.  
<sup>b</sup>Models are adjusted for SCORE2 risk factors: age, smoking status, systolic blood pressure, diabetes mellitus, total cholesterol, and high-density lipoprotein.  
<sup>c</sup>Hazard ratio for the specified biomarker (adjusted model) divided by the hazard ratio for NT-proBNP (adjusted model). This model tests which of the biomarkers have evidence of stronger or weaker adjusted associations with MACE compared to NT-proBNP.

et al. previously assessed 30 candidate biomarkers in relation to cardiovascular risk prediction in a smaller study (n = 7915) and found that NT-proBNP, cTnI, and CRP when added to established risk factors improved performance when compared to a baseline model in men (13). We extended current knowledge by conducting a comprehensive sex- and age-specific analysis, and showed that NT-proBNP, combined particularly with GDF-15 or cTnI, showed greatest improvement in prediction of cardiovascular risk compared to a baseline model for both women and men and all age groups. A biomarker-driven strategy that uses NT-proBNP combined with GDF-15 or cTnI may contribute to further improvement in cardiovascular risk assessment.

Sex disparities in primary prevention and treatment of cardiovascular disease exists (38, 39), and using a biomarker-driven risk assessment approach may reduce the gap between women and men. In line with previous studies (17–19), we observed important sex-differences in cardiac biomarker concentrations and in their association with MACE. While for NT-proBNP, GDF-15, and CRP higher baseline concentrations were observed in women, higher cTnI and cTnT concentrations were observed in men. We also found that the association between all cardiac biomarkers and MACE was numerically stronger in women than men, but this divergence diminished after adjustment for cardiovascular risk factors. These observations are particularly important with respect to integration of cardiac biomarkers in our cardiovascular risk estimation systems. A binary approach that uses a uniform cardiac biomarker threshold will not contribute to reduce current inequalities, but rather may increase the existing gap. In previous research we showed that age and other cardiovascular risk factors like diabetes and body mass index are important modifying factors between sex, cardiac biomarkers, and clinical outcomes (22, 40, 41). Altogether, this indicates that an approach using sex-specific thresholds to predict cardiovascular disease in the primary care setting is also too simplistic. The digitalization of electronic health records enables the opportunity to embed cardiovascular risk estimation systems that includes cardiac biomarkers as a continuous variable together with other cardiovascular risk factors and preventative therapies for use in clinical practice. Evaluation of implementation of biomarker-driven risk assessment tools in practice is required and an important step to assess the impact of these tools on care for women and men.

Our findings suggest that cTnT, CRP, and creatinine are the weakest independent predictors in a presumably healthy population and are less useful for cardiovascular risk assessment. Although the underlying mechanisms are not well understood, cTnT seems to be more strongly associated with noncardiovascular disease like chronic kidney disease and muscular disease than



cTnI (42, 43). We also found that CRP marginally improved risk prediction for men but not for women. This is in line with the findings of a large study that included 246 669 individuals who were presumed to be healthy, which showed that the change in c-index for CRP when added to a base model was +0.0077 (+0.0058 to 0.0096) for men and +0.0007 (−0.0007 to 0.0021) for women (44). Altogether, this indicates that the use of cTnT and CRP for cardiovascular risk

estimation may be less incrementally beneficial than other cardiac biomarkers. It should be noted that CRP has been added to the secondary prevention SMART2 risk score (45).

In this study, we report that a model including established cardiovascular risk factors performed well with excellent discrimination and a c-index of approximately 0.8 for both women and men. This is likely at least in part due to the wide age range of our cohort.



This level of discrimination in a risk score makes it very difficult to demonstrate incremental value with the addition of cardiac biomarkers, and to explain the modest increments in the c-index that they determined. Despite this, our data indicates that the use of NT-proBNP, GDF-15, and cTnI provide additional prognostic information not captured currently by established risk factors. The NRI suggests improved risk classification among cases, which would lead to more appropriate and intensive treatments for those who require it most. The complementary information provided by these disease-specific biomarkers can therefore further enhance patient and clinician understanding of the impact of risk factors on the cardiovascular system and may help target interventions to those individuals who are at high risk of a future cardiovascular event. For incorporation of cardiac biomarkers into cardiovascular risk scores, it should be taken into account that the gain of adding cardiac biomarkers to risk scores seems highest for individuals  $\geq 40$  years old. Other options for refining cardiovascular risk include the use of coronary artery calcification (CAC) score. A recent meta-analysis suggested that the c-index of a base model was improved by +0.036 with the addition of the CAC score, although the base model performance was lower in this study (range: 0.693 to 0.800) and heterogeneity of the estimated improvement in discrimination was high (46). To get a better understanding of the clinical implications of our study, additional research is needed on the costs, risks, and benefits of using combined cardiac biomarkers or CAC scoring for cardiovascular risk refinement.

Our study has several limitations. First, the GS:SFHS cohort includes predominantly White individuals, limiting generalizability of our findings to other ethnicities. Second, our analysis is restricted to 2 manufacturers' assays and direct extrapolation of our findings to other manufacturers' assay cannot be made. Third, biomarker measurements were only available at one point in time; we could not evaluate the relationship between biomarker trajectories and cardiovascular risk. Finally, we have used the SCORE2 outcome of MACE that does not include heart failure. Future research should evaluate the ability of biomarkers to predict the onset of heart failure, which may be the first manifestation of cardiovascular disease.

In conclusion, cardiac biomarkers—particularly NT-proBNP, GDF-15, and cTnI—further refined cardiovascular risk estimates compared to a currently recommended model using traditional risk factors. A biomarker-driven strategy that uses NT-proBNP vcombined with GDF-15 or cTnI may contribute to further improvement in cardiovascular risk assessment for prevention of cardiovascular disease in women and men.

## Supplemental Material

Supplemental material is available at *Clinical Chemistry* online.

**Nonstandard Abbreviations:** NT-proBNP, N-terminal pro-B-type natriuretic peptide; GDF-15, growth differentiation factor-15; cTnI, cardiac troponin I; cTnT, cardiac troponin T; CRP, C-reactive protein; MACE, major adverse cardiovascular events; GS:SFHS, Generation Scotland Scottish Family Health study; LOD, limit of detection; LOB, limit of blank; IDI, integrated discrimination index; NRI, net reclassification index.

**Author Contributions:** *The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list.*

Paul Welsh (Conceptualization-Equal, Funding acquisition-Equal, Investigation-Lead, Project administration-Equal, Writing—original draft-Equal), Dorien Kimenai (Conceptualization-Equal, Formal analysis-Lead, Methodology-Equal, Project administration-Equal, Writing—original draft-Equal), Anoop Shah (Conceptualization-Equal, Writing—review & editing-Equal), Danni A Gadd (Conceptualization-Supporting, Writing—review & editing-Equal), Riccardo Marioni (Conceptualization-Supporting, Writing—review & editing-Equal), Mark Woodward (Conceptualization-Supporting, Formal analysis-Supporting, Writing—review & editing-Equal), Cathie L.M. Sudlow (Conceptualization-Supporting, Writing—review & editing-Equal), Archie Campbell (Data curation-Lead, Writing—review & editing-Equal), John G.F. Cleland (Conceptualization-Supporting, Writing—review & editing-Equal), Pierpaolo Pellicori (Conceptualization-Supporting, Writing—review & editing-Equal), Caroline Hayward (Conceptualization-Supporting, Writing—review & editing-Equal), Nicholas Mills (Conceptualization-Equal, Supervision-Equal, Writing—review & editing-Equal), and Naveed Sattar (Conceptualization-Equal, Funding acquisition-Equal, Supervision-Equal, Writing—review & editing-Equal)

**Authors' Disclosures or Potential Conflicts of Interest:** *Upon manuscript submission, all authors completed the author disclosure form.*

**Research Funding:** Roche Diagnostics supported this study through provision of free reagents and a grant for measurement of NT-proBNP, CRP, and GDF-15. Troponin measurements and analysis were supported by a Stratified Medicine Grant from the Chief Scientist Office of the Scottish Government Health Directorates (ASM/14/1). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). D.M. Kimenai is supported by a British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/23/25161), and by Health Data Research UK, which receives its funding from HDR UK Ltd (HDR5012) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist

Office of the Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Foundation, and the Wellcome Trust. C. Hayward is supported by an MRC University Unit Programme Grant MC\_UU\_00007/10 (QTL in Health and Disease). N.L. Mills is supported by the British Heart Foundation through a Chair Award (CH/F/21/90010), Programme Grant (RG/20/10/34966), and a Research Excellent Award (RE/18/5/34216). A.S.V. Shah is supported by the British Heart Foundation through an Intermediate Clinical Research Fellowship (FS/19/17/34172). C.L.M. Sudlow received a £5M Wellcome Trust (major research funding charity) longitudinal studies award to University of Edinburgh 2019–2024 for enhancement, extension, and maintenance of the Generation Scotland study (PI). D.A. Gadd is funded by the Wellcome Trust 4-year PhD in Translational Neuroscience—training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. M. Woodward is supported by the Australian National Health and Medical Research Council (APP1149987, APP1174120).

**Disclosures:** P. Welsh reports grant income from Roche Diagnostics in relation to and outside of the submitted work, as well as grant income from AstraZeneca, Boehringer Ingelheim, and Novartis, outside the submitted work and speaker fees from Novo Nordisk and Raisio outside the submitted work. D.A. Gadd has received consultancy fees from Optima Partners. R.E. Marionni has received speaker fees from Illumina and is an advisor to the Epigenetic Clock Development Foundation and Optima Partners. M. Woodward has recently been a consultant to Amgen and Freeline. C.L.M. Sudlow disclosed MRC and multiple partner funders: Health Data Research UK Core Funding (Co-I), Stroke Association: Stroke Data Science Catalyst for BHF Data Science Centre (PI), Diabetes UK: Diabetes Data Science Catalyst for BHF Data Science Centre (PI), BHF Data Science Centre (Centre Director), MRC: Relationship between depression and physical multimorbidity in UKB (Co-I), HDR UK National Phenomics & Text Analytics Initiatives and Digital Innovation Hub, Knowledge Graph Sprint Exemplar (Co-I), University of Edinburgh UKRI Centre for Doctoral Training in Biomedical AI (Co-I), BHF: Edinburgh BHF Centre of Research Excellence (Co-I), Wellcome Trust: Clinical Research Career

Development Fellowship, (sponsor, Dr D Breen: Sleep, circadian rhythm and brain health), CRUK: University of Edinburgh & UCL Brain Cancer Centre of Excellence (Co-I), HDR UK Scottish Substantive Site and HDR UK Fellowships (PI), MRC: Pathomolecular mechanisms of intracerebral haemorrhage (Co-I), MRC: Mental Health Data Science Pathfinder Award (Co-I), Wellcome Trust and MRC Clinical Research Career Development, & Training Fellowships x3 (primary supervisor/sponsor), MRC, Wellcome Trust, BHF, CRUK: UK Biobank Core Renewal & Imaging study (Co-I). A.S.V. Shah's institution has received honoraria from Abbott Diagnostics outside the submitted work. J.G.F. Cleland has received research funding and personal honoraria from Boehringer-Ingelheim, Moderna, Novartis, Bristol Myers Squibb, Medtronic, Pharmacosmos, and Vifor outside the submitted work and served on the guidelines committee on heart failure for the European Society of Cardiology. N.L. Mills has received personal fees from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, and LumiraDx, and has received a grant awarded to the University of Edinburgh from Abbott Diagnostics and Siemens Healthineers outside the submitted work. N. Sattar has consulted for and/or received speaker honoraria from Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work.

**Role of Sponsor:** The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.

**Acknowledgments:** We thank all families who took part, general practitioners, and the Scottish School of Primary Care for their help in recruiting them, and the Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants, and nurses. We thank Elaine Butler, Emma Dunning, and Philip Stewart, University of Glasgow, for their expert technical work.

## References

1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Böck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42:3227–337.
2. Tsao CW, Aday AW, Almarazooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. *Circulation* 2022;145:e153–639.
3. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac troponin T and troponin I in the general population. *Circulation* 2019;139:2754–64.
4. Neumann JT, Twerenbold R, Ojeda F, Sörensen NA, Chapman AR, Shah ASV, et al. Application of high-sensitivity troponin in suspected myocardial infarction. *N Engl J Med* 2019;380:2529–40.
5. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *N Engl J Med* 2009;361:2538–47.
6. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. *Eur Heart J* 2016;37:2428–37.
7. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. *J Am Coll Cardiol* 2017;70:558–68.
8. Berry JD, Nambi V, Ambrosius WT, Chen H, Killeen AA, Taylor A, et al. Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial. *JAMA Cardiol* 2021;6:1397–405.
9. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA* 2010;304:2503–12.
10. Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. *Circulation* 2019;139:2642–53.
11. Daniels LB, Clopton P, deFilippi CR, Sanchez OA, Bahrami H, Lima JAC, et al. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2015;170:1170–83.
12. Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth A, Chowdhury R, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol* 2016;4:840–9.
13. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population

- cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. *Circulation* 2010;121:2388–97.
14. Lind L, Zanetti D, Ingelsson M, Gustafsson S, Ärnlöv J, Assimes TL. Large-scale plasma protein profiling of incident myocardial infarction, ischemic stroke, and heart failure. *J Am Heart Assoc* 2021;10:e023330.
  15. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006;355:2631–9.
  16. de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Gregory Hundley W, et al. Multimodality strategy for cardiovascular risk assessment: performance in 2 population-based cohorts. *Circulation* 2017;135:2119–32.
  17. Kimenai DM, Shah ASV, McAllister DA, Lee KK, Tsanas A, Meex SJR, et al. Sex differences in cardiac troponin I and T and the prediction of cardiovascular events in the general population. *Clin Chem* 2021;67:1351–60.
  18. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JS, Nygård S, et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. *Clin Chem* 2015;61:646–56.
  19. Zhu F, Arshi B, Leening MJG, Aribas E, Ikram MA, Boersma E, et al. Sex-specific added value of cardiac biomarkers for 10-year cardiovascular risk prediction. *Eur J Prev Cardiol* 2022;29:1559–67.
  20. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. *Int J Epidemiol* 2013;42:689–700.
  21. Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, et al. Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. *BMC Med Genet* 2006;7:74.
  22. Welsh P, Kimenai DM, Marioni RE, Hayward C, Campbell A, Porteous D, et al. Reference ranges for GDF-15, and risk factors associated with GDF-15, in a large general population cohort. *Clin Chem Lab Med* 2022;60:1820–9.
  23. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ* 2015;350:g7873.
  24. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;145:e895–e1032.
  25. Kastritis E, Papassotiropoulos I, Merlini G, Milani P, Terpos E, Basset M, et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. *Blood* 2018;131:1568–75.
  26. National Institute for Health and Care Excellence. High-sensitivity troponin tests for the early rule out of NSTEMI. <https://www.nice.org.uk/guidance/dg40> (Accessed April 2023).
  27. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;391:319–28.
  28. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 Risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J* 2021;42:2439–54.
  29. Scottish Government. The Scottish index of multiple deprivation 2020. <https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/> (Accessed April 2023).
  30. Gore MO, Ayers CR, Khara A, deFilippi CR, Wang TJ, Seliger SL, et al. Combining biomarkers and imaging for short-term assessment of cardiovascular disease risk in apparently healthy adults. *J Am Heart Assoc* 2020;9:e015410.
  31. Saeed A, Nambi V, Sun W, Virani SS, Taffet GE, Deswal A, et al. Short-term global cardiovascular disease risk prediction in older adults. *J Am Coll Cardiol* 2018;71:2527–36.
  32. Wu Z, Pilbrow AP, Liew OW, Chong JPC, Sluyter J, Lewis LK, et al. Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. *EBioMedicine* 2022;82:104170.
  33. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med* 2008;358:2107–16.
  34. Frary CE, Blicher MK, Olesen TB, Stidsen JV, Greve SV, Vishram-Nielsen JK, et al. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort. *Eur J Prev Cardiol* 2020;27:570–8.
  35. Bozkurt B. It is time to screen for heart failure: why and how? *JACC Heart Fail* 2022;10:598–600.
  36. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. *Circulation* 2012;126:1596–604.
  37. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. *Clin Chem* 2017;63:140–51.
  38. Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex differences in the use of statins in community practice. *Circ Cardiovasc Qual Outcomes* 2019;12:e005562.
  39. Hyun KK, Redfern J, Patel A, Peiris D, Brieger D, Sullivan D, et al. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. *Heart* 2017;103:492–8.
  40. Welsh P, Campbell RT, Mooney L, Kimenai DM, Hayward C, Campbell A, et al. Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. *Circ Heart Fail* 2022;15:e009427.
  41. de Bakker M, Anand A, Shipley M, Fujisawa T, Shah ASV, Kardys I, et al. Sex differences in cardiac troponin trajectories over the life course. *Circulation* 2023;13:1798–808.
  42. Starnberg K, Friden V, Muslimovic A, Ricksten S, Nyström S, Forsgard N, et al. A possible mechanism behind faster clearance and higher peak concentrations of cardiac troponin I compared with troponin T in acute myocardial infarction. *Clin Chem* 2020;66:333–41.
  43. Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. *J Am Coll Cardiol* 2018;71:1540–9.
  44. Emerging Risk Factors Collaborators, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med* 2012;367:1310–20.
  45. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. *Eur Heart J* 2022;43:1715–27.
  46. Bell KJL, White S, Hassan O, Zhu L, Scott AM, Clark J, et al. Evaluation of the incremental value of a coronary artery calcium score beyond traditional cardiovascular risk assessment: a systematic review and meta-analysis. *JAMA Intern Med* 2022;182:634–42.